CTOs on the Move

Onyx Pharmaceuticals

www.onyx.com

 
At Onyx Pharmaceuticals, an Amgen subsidiary, our imperative is to build a leading cancer therapeutics company like no other, working toward a unified goal that drives us forward…to deliver breakthrough cancer treatments to patients with the urgency they deserve.   By working in collaboration with patient advocacy groups, healthcare providers and business partners, we push the boundaries of science and cancer therapeuticdevelopment.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.onyx.com
  • 249 E. Grand Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.266.0000

Executives

Name Title Contact Details

Similar Companies

Stonewood Village Pharmacy

Stonewood Village Pharmacy is a Fort Smith, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zerigo Health

Our Zerigo Health Solution is the newest advance in the treatment of psoriasis, vitiligo & eczema - available at-home for your convenience!

Sagimet

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors.

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

Weedmaps

Founded in 2008, Weedmaps is a leading technology and software infrastructure provider to the cannabis industry. Our suite of cloud-based software and data solutions includes point of sale, logistics and ordering solutions that enable customers to scale their businesses while complying with the complex and disparate regulations applicable to the cannabis industry. In addition, our platform provides consumers with information regarding cannabis products across web and mobile platforms, including listing local retailers and brands, facilitating product discovery and allowing consumers to educate themselves on cannabis and its history, uses and legal status. Headquartered in Irvine, California, Weedmaps employs more than 400 professionals around the world, with offices including Barcelona, Denver, and Toronto.